Anti-Rheumatic Drug when Others Have not Worked
common.study.values.description
“A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy”
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in subjects with moderately to severely active psoriatic arthritis (PsA).
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-yes
Biological - placebo for rizankizumab
Placebo for risankizumab administered by subcutaneous (SC) injection
Biological - risankizumab
Risankizumab administered by subcutaneous (SC) injection
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
common.study.values.clinical-trial-id
NCT03675308
participant.views.study.view.id
e739re
